ADMA's Share Price Plummets Amid Serious Allegations and Investigation
Mar 30, 2026, 4:02 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Historical examples show that similar allegations lead to sharp declines in stock prices; the sustained nature of investigations can further depress shares, making this a significantly bearish development.
AI summary
What happened, with direct paths to the underlying reporting
ADMA Biologics faced a 16% stock drop after allegations of financial misconduct surfaced. Hagens Berman is investigating potential violations of securities laws, which could severely impact investor confidence and ADMA's financials.
ADMA's stock dropped over 16% following Culper Research's allegations.
Culper claims ADMA engaged in channel stuffing to inflate revenues.
Hagens Berman is investigating possible violations of federal securities laws.
Days sales outstanding rose to 113 days, signaling financial distress.
Reported growth may not be genuine as real growth was -3.5% in 2025.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
ADMA Biologics targets immune-compromised patients with plasma-derived products. They have three FDA-approved drugs and operate in a promising immunoglobulin market.
StockNews.AISignal intelligence